A23V2250/1846

METHOD FOR REDUCING AMOUNT OF SUGAR USED IN CHOCOLATE
20230232857 · 2023-07-27 · ·

A method for enhancing the sweetness of sugar in chocolate that contains a prescribed amount of sugar, to thereby reduce the amount of sugar used. Upon thoroughly investigating a resolution to the abovementioned problem, the inventor discovered that incorporating a prescribed amount of phosphatidylcholine in chocolate that contains a prescribed amount of sugar makes it possible to enhance the sweetness of the sugar, resultantly making it possible to reduce the amount of sugar used.

NUTRACEUTICAL OR PHARMACEUTICAL COMPOSITION COMPRISING IRON PYROPHOSPHATE FOR TREATING AND/OR PREVENTING IRON DEFICIENCY CONDITIONS OR DISEASES
20230000907 · 2023-01-05 ·

Provided herein is a composition of substances preferably obtained from natural sources, which is effective in preventing and/or treating iron deficiency conditions or diseases. The composition includes iron pyrophosphate, phosphatidylserine, phosphatidylcholine and starch, preferably acetylated pregelatinised starch. The formulation gives the composition gastro-resistance properties and high bioavailability of the active ingredient iron pyrophosphate. The composition is prepared in the form of a solid, semi-solid or liquid pharmaceutical dosage, preferably for oral administration.

NUTRACEUTICAL OR PHARMACEUTICAL COMPOSITION COMPRISING IRON PYROPHOSPHATE FOR TREATING AND/OR PREVENTING IRON DEFICIENCY CONDITIONS OR DISEASES
20230000907 · 2023-01-05 ·

Provided herein is a composition of substances preferably obtained from natural sources, which is effective in preventing and/or treating iron deficiency conditions or diseases. The composition includes iron pyrophosphate, phosphatidylserine, phosphatidylcholine and starch, preferably acetylated pregelatinised starch. The formulation gives the composition gastro-resistance properties and high bioavailability of the active ingredient iron pyrophosphate. The composition is prepared in the form of a solid, semi-solid or liquid pharmaceutical dosage, preferably for oral administration.

COMPOSITIONS AND THEIR USE
20220378078 · 2022-12-01 ·

A synthetic nutritional composition comprising a vitamin for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.

COMPOSITIONS AND THEIR USE
20220378078 · 2022-12-01 ·

A synthetic nutritional composition comprising a vitamin for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.

HOMOGENOUS COMPOSITION AND METHODS OF MAKING THE SAME
20170326077 · 2017-11-16 ·

A hydrated lecithin carrier vesicle composition includes a lecithin-derived membrane-forming lipid vesicle in conditioned water for incorporation of an active ingredient to form a dispersed composition. A method of making the hydrated lecithin carrier vesicle includes using lecithin having not more than about 80% w/w phosphatidylcholine in the presence of conditioned water.

HOMOGENOUS COMPOSITION AND METHODS OF MAKING THE SAME
20170326077 · 2017-11-16 ·

A hydrated lecithin carrier vesicle composition includes a lecithin-derived membrane-forming lipid vesicle in conditioned water for incorporation of an active ingredient to form a dispersed composition. A method of making the hydrated lecithin carrier vesicle includes using lecithin having not more than about 80% w/w phosphatidylcholine in the presence of conditioned water.

Product for use in the prophylactic or therapeutic treatment of a negative emotion or introvert behaviour
09795628 · 2017-10-24 · ·

The invention relates to a nutritional composition comprising dietary fiber, a peptide having 7 or more amino acid units, the nutritional composition comprising a tryptophan source, which may be said peptide or different there from, for use in the treatment of a negative emotion or introvert behavior. The invention further relates to a combination of dietary fiber, a peptide having 7 or more amino acid units, the nutritional composition comprising a tryptophan source, which may be said peptide or different there from, and optionally one or more other components, for use in the treatment of a negative emotion or introvert behavior.

Product for use in the prophylactic or therapeutic treatment of a negative emotion or introvert behaviour
09795628 · 2017-10-24 · ·

The invention relates to a nutritional composition comprising dietary fiber, a peptide having 7 or more amino acid units, the nutritional composition comprising a tryptophan source, which may be said peptide or different there from, for use in the treatment of a negative emotion or introvert behavior. The invention further relates to a combination of dietary fiber, a peptide having 7 or more amino acid units, the nutritional composition comprising a tryptophan source, which may be said peptide or different there from, and optionally one or more other components, for use in the treatment of a negative emotion or introvert behavior.

N-acyl-phosphatidyl-ethanolamines and/or mixtures of N-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids

Pharmaceutical, cosmetic and dietetic compositions and functional foods, constituted by: A) phospholipid mixtures containing N-acyl-phosphatidyl-ethanolamines (NAPEs) and/or B) phospholipid mixtures containing N-acyl-ethanol amines (NAEs) together with phosphatidic acids (PAs) and/or lysophosphatidic acids (LPAs) with the proviso that said N-acyl-phosphatidyl-ethanolamines (NAPEs) do not include N-oleoyl-phosphatidyl-ethanolamine. New phosphobioflavonic complexes of NAPE or NAE with one or more bioflavonoids are also disclosed.